Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II trial of weekly nab-paclitaxel for previously treated advanced non-small cell lung cancer: Kumamoto thoracic oncology study group (KTOSG) trial 1301.
Sakata S, Saeki S, Okamoto I, Otsubo K, Komiya K, Morinaga R, Yoneshima Y, Koga Y, Enokizu A, Kishi H, Hirosako S, Yamaguchi E, Aragane N, Fujii S, Harada T, Iwama E, Semba H, Nakanishi Y, Kohrogi H. Sakata S, et al. Among authors: morinaga r. Lung Cancer. 2016 Sep;99:41-5. doi: 10.1016/j.lungcan.2016.06.009. Epub 2016 Jun 14. Lung Cancer. 2016. PMID: 27565912 Clinical Trial.
Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
Okamoto I, Miyazaki M, Morinaga R, Kaneda H, Ueda S, Hasegawa Y, Satoh T, Kawada A, Fukuoka M, Fukino K, Tanigawa T, Nakagawa K. Okamoto I, et al. Among authors: morinaga r. Invest New Drugs. 2010 Dec;28(6):844-53. doi: 10.1007/s10637-009-9321-x. Epub 2009 Sep 18. Invest New Drugs. 2010. PMID: 19760364 Free PMC article. Clinical Trial.
Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors.
Okamoto I, Kaneda H, Satoh T, Okamoto W, Miyazaki M, Morinaga R, Ueda S, Terashima M, Tsuya A, Sarashina A, Konishi K, Arao T, Nishio K, Kaiser R, Nakagawa K. Okamoto I, et al. Among authors: morinaga r. Mol Cancer Ther. 2010 Oct;9(10):2825-33. doi: 10.1158/1535-7163.MCT-10-0379. Epub 2010 Aug 5. Mol Cancer Ther. 2010. PMID: 20688946 Clinical Trial.
Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B.
Hayashi H, Tsurutani J, Satoh T, Masuda N, Okamoto W, Morinaga R, Terashima M, Miyazaki M, Okamoto I, Nishida Y, Tominaga S, Tokunaga Y, Yamaguchi M, Sakamoto J, Nakayama T, Nakagawa K. Hayashi H, et al. Among authors: morinaga r. Breast Cancer. 2013 Apr;20(2):131-6. doi: 10.1007/s12282-011-0316-z. Epub 2011 Nov 29. Breast Cancer. 2013. PMID: 22124996 Clinical Trial.
Phase II trial of erlotinib for Japanese patients with previously treated non-small-cell lung cancer harboring EGFR mutations: results of Lung Oncology Group in Kyushu (LOGiK0803).
Yamada K, Takayama K, Kawakami S, Saruwatari K, Morinaga R, Harada T, Aragane N, Nagata S, Kishimoto J, Nakanishi Y, Ichinose Y. Yamada K, et al. Among authors: morinaga r. Jpn J Clin Oncol. 2013 Jun;43(6):629-35. doi: 10.1093/jjco/hyt056. Epub 2013 Apr 18. Jpn J Clin Oncol. 2013. PMID: 23599349 Clinical Trial.
Alectinib for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status (Lung Oncology Group in Kyushu 1401).
Iwama E, Goto Y, Murakami H, Harada T, Tsumura S, Sakashita H, Mori Y, Nakagaki N, Fujita Y, Seike M, Bessho A, Ono M, Okazaki A, Akamatsu H, Morinaga R, Ushijima S, Shimose T, Tokunaga S, Hamada A, Yamamoto N, Nakanishi Y, Sugio K, Okamoto I. Iwama E, et al. Among authors: morinaga r. J Thorac Oncol. 2017 Jul;12(7):1161-1166. doi: 10.1016/j.jtho.2017.02.012. Epub 2017 Feb 24. J Thorac Oncol. 2017. PMID: 28238961 Free article. Clinical Trial.
Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor-naïve patients with non-small cell lung cancer harboring EGFR mutations.
Tanaka K, Nosaki K, Otsubo K, Azuma K, Sakata S, Ouchi H, Morinaga R, Wataya H, Fujii A, Nakagaki N, Tsuruta N, Takeshita M, Iwama E, Harada T, Nakanishi Y, Okamoto I. Tanaka K, et al. Among authors: morinaga r. Oncotarget. 2017 Jul 12;8(40):68123-68130. doi: 10.18632/oncotarget.19243. eCollection 2017 Sep 15. Oncotarget. 2017. PMID: 28978102 Free PMC article.
Phase I/II study of carboplatin plus nab-paclitaxel and concurrent radiotherapy for patients with locally advanced non-small cell lung cancer.
Kawano Y, Sasaki T, Yamaguchi H, Hirano K, Horiike A, Satouchi M, Hosokawa S, Morinaga R, Komiya K, Inoue K, Fujita Y, Toyozawa R, Kimura T, Takahashi K, Nishikawa K, Kishimoto J, Nakanishi Y, Okamoto I. Kawano Y, et al. Among authors: morinaga r. Lung Cancer. 2018 Nov;125:136-141. doi: 10.1016/j.lungcan.2018.09.014. Epub 2018 Sep 18. Lung Cancer. 2018. PMID: 30429011 Clinical Trial.
54 results